Clinical trials: PRF
Acromegaly
Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly
The objectives of the protocol is to determine the maximum tolerated dose and to investigate the pharmacokinetics of a single dose of lanreotide PRF in subjects with acromegaly.
- Trial name
- NCT02396953
- Testing
- Lanreotide PRF
- Where
- 36 sites in Belgium, Czechia and 10 more
- Volunteers
- 28 people
- Sponsor
- Ipsen